Participated in the US anti-fibrotic treatment development conference
Announcement of non-clinical research data for new drug candidate ‘IL21120038’
Presentation of new mechanism ‘CXCR7 agonist’
Expected to be effective in treating not only heart but also lung and liver fibrosis
Ildong Pharmaceutical Group announced on the 22nd that iLeadBMS, a new drug research and development subsidiary, disclosed the latest research results on new drug candidates in the field of heart disease at an international academic conference. Non-clinical research results were made public, suggesting a new mechanism in the anti-fibrotic field and confirming the possibility of developing new drugs.
ILead BMS participated in the ‘Antifibrotic Drug Development Summit (AFDD)’ held in Boston, USA from the 19th (local time) to the 21st and presented non-clinical research data on the new drug candidate ‘IL21120038’. A poster was presented.
IL21120038 is an anti-fibrotic new drug candidate based on a small molecule compound that acts on CXCR7 (CXC chemokine receptor 7), which is closely involved in causing tissue fibrosis and inflammation among the chemokine receptors, a type of immune-related signaling protein. CXCR7 is known to play an important role in suppressing the death of cardiomyocytes when ischemia or damage occurs in the heart.
The candidate substance is a CXCR7 agonist drug that shows high binding selectivity to CXCR7, which is prominently expressed in cardiomyocytes, and shows anti-inflammatory and anti-fibrotic effects by removing CXCL12 (CXC motif chemokine 12), an inflammation-causing factor.
According to the poster presentation, the results of a non-clinical study on a myocardial infarction model using laboratory rats showed that IL21120038 significantly reduced the infarct area in the left ventricle. In addition, the levels of creatine kinase-MB3 (CK-MB3) and cardiac troponin I (cTnI), indicators of heart damage, were found to be significantly lowered. It is said that the effect of alleviating inflammation and fibrosis along with increasing cardiac output was confirmed.
Ilead BMS reported that IL21120038 showed better improvement in a test compared to Entresto (ingredient names: sacubitril and valsartan), an existing drug widely used to treat cardiovascular diseases such as heart failure.
iLead BMS announced that it has confirmed the potential of an innovative new drug (first-in-class) to treat various heart diseases caused by fibrosis, such as ischemic heart disease, arrhythmia, and heart failure, through non-clinical research. Accordingly, the plan is to begin preparing all requirements necessary for applying for clinical trial (IND) approval, including safety evaluation (GLP) testing.
In addition to heart disease, the possibility of treating lung and liver diseases is also open. Non-clinical studies involving CXCR7 agonists also confirmed the therapeutic effect on lung and liver fibrosis. The research results were made public at the American Thoracic Society (ATS) and European Association for the Liver Association (EASL) held earlier.
MeMS plans to participate in the JP Morgan Healthcare Conference held in the United States in January next year and discuss commercialization, such as joint development and out-licensing, with global pharmaceutical companies.
Kim Min-beom, Donga.com reporter [email protected]
- I’m angry
- 0dog
- I recommend it
- dog
Hot news now
How does IL21120038 compare to current anti-fibrotic therapies for heart, lung, and liver diseases?
Interview Transcript: Time.news Editor and Dr. Emily Chen, Expert in Anti-Fibrotic Treatments
Time.news Editor: Thank you for joining us today, Dr. Chen. We’re excited to discuss the recent findings presented by Ildong Pharmaceutical Group regarding their new drug candidate, IL21120038. To start, could you share what makes this drug candidate so significant in the field of anti-fibrotic treatments?
Dr. Chen: Absolutely! IL21120038 represents a promising development in anti-fibrotic therapy, particularly because it targets CXCR7, a chemokine receptor that plays a crucial role in tissue fibrosis and inflammation. Its unique mechanism as a CXCR7 agonist sets it apart from existing treatments, not only for heart disease but also for potential lung and liver applications.
Time.news Editor: That’s intriguing. The research was presented at the Antifibrotic Drug Development Summit in Boston. Could you elaborate on the findings related to heart disease? What were the key results from the non-clinical studies?
Dr. Chen: Of course. The non-clinical study utilized a myocardial infarction model with laboratory rats, and the results were quite promising. IL21120038 significantly reduced the infarct area in the left ventricle and lowered levels of cardiac damage indicators such as creatine kinase-MB3 and cardiac troponin I. These results suggest that the drug not only helps in reducing the damage caused by heart attacks but also improves overall cardiac function by alleviating inflammation.
Time.news Editor: You mentioned that IL21120038 displayed better improvements compared to Entresto, a commonly used heart failure medication. How does this compare to existing treatments in terms of efficacy?
Dr. Chen: The fact that IL21120038 showed superior efficacy in reducing heart damage markers compared to Entresto is quite significant. While Entresto is effective, IL21120038’s mechanism may offer a more targeted approach by addressing both inflammation and fibrosis at the cellular level. This could lead to better patient outcomes, particularly in those with heart conditions linked to fibrosis.
Time.news Editor: Beyond its effects on heart conditions, there’s also mention of its potential in treating lung and liver fibrosis. How does a focus on CXCR7 suggest effectiveness in these other areas?
Dr. Chen: CXCR7 has been implicated in various fibrosis-related diseases, not just in the heart. Studies presented at the American Thoracic Society and the European Association for the Liver Association indicated that CXCR7 modulation could help mitigate fibrosis in both lung and liver tissues. This broadened therapeutic potential could make IL21120038 a first-in-class agent with wide-ranging applications in fibrotic diseases.
Time.news Editor: That’s an ambitious outlook. What are the next steps for ILead BMS regarding IL21120038?
Dr. Chen: ILead BMS is currently preparing for the next phase, which involves gathering all necessary requirements for applying for clinical trial approval, including detailed safety evaluations. If successful, this could pave the way for clinical trials that will ultimately determine the safety and efficacy of IL21120038 in humans.
Time.news Editor: With such promising results, how do you see the future of anti-fibrotic therapies evolving, especially with innovations like IL21120038?
Dr. Chen: I believe we’re on the cusp of a new era in anti-fibrotic therapy. Innovations like IL21120038 could lead to more personalized treatments that not only target the disease at its source but also minimize side effects associated with traditional therapies. As research in this field progresses, we may see a significant shift in how we approach and manage fibrotic diseases across multiple organ systems.
Time.news Editor: Thank you, Dr. Chen, for sharing your insights. It’s clear that the work being done with IL21120038 could be a game changer in the fight against fibrosis-related diseases.
Dr. Chen: Thank you for having me! The potential for improved patient outcomes is truly exciting, and I look forward to seeing how this research develops.